'Masked hypertension' is defined as having non-elevated clinic blood pressure (BP) with elevated out-of-clinic average BP, typically determined by ambulatory BP monitoring. Approximately 15-30% of adults with non-elevated clinic BP have masked hypertension. Masked hypertension is associated with increased risks of cardiovascular morbidity and mortality compared with sustained normotension (non-elevated clinic and ambulatory BP), which is similar to or approaching the risk associated with sustained hypertension (elevated clinic and ambulatory BP). The confluence of increased cardiovascular risk and a failure to be diagnosed by the conventional approach of clinic BP measurement makes masked hypertension a significant public health concern. However, many important questions remain. First, the definition of masked hypertension varies across studies. Further, the best approach in the clinical setting to exclude masked hypertension also remains unknown. It is unclear whether home BP monitoring is an adequate substitute for ambulatory BP monitoring in identifying masked hypertension. Few studies have examined the mechanistic pathways that may explain masked hypertension. Finally, scarce data are available on the best approach to treating individuals with masked hypertension. Herein, we review the current literature on masked hypertension including definition, prevalence, clinical implications, special patient populations, correlates, issues related to diagnosis, treatment and areas for future research.
INTRODUCTION
Traditionally, the diagnosis of hypertension is based on clinic blood pressure (BP), but the use of ambulatory BP monitoring (ABPM) along with clinic BP has made the classification of hypertension more complex. The correlation between BP taken during routine clinic visits and ambulatory BP is only moderate. 1 Thus, many individuals exhibit a large discrepancy between these two measures. Figure 1 shows the four possible BP categorizations derived from the combination of clinic and average ambulatory BP. For two of the categories-sustained hypertension and sustained normotension-the classification is concordant by the two methods of BP measurement. In the other two categories-white coat hypertension and masked hypertension-the classification by the two methods is discordant. Pickering 2 first introduced the concept of white coat hypertension more than 25 years ago, which is defined as having high clinic BP but normal ambulatory BP. White coat hypertension occurs in 15-25% of people who are thought to be hypertensive by clinic measurement. 3 The risk of cardiovascular disease (CVD) events in patients with white coat hypertension is relatively low compared with patients with sustained hypertension, although there has been some dispute about whether white coat hypertension is a benign phenotype. 3, 4 In 2002, Pickering and his co-workers 5 coined the term 'masked hypertension' to describe the condition of non-elevated clinic BP with elevated average ambulatory BP. Unlike white coat hypertension, masked hypertension has consistently been shown to be associated with a greater risk of CV target-organ damage, CVD and mortality, compared with sustained normotension.
Although masked hypertension is increasingly being recognized as an important clinical entity, many questions remain. Herein, we review the current literature on masked hypertension, including definition, prevalence, clinical implications, issues with diagnosis, correlates, treatment and areas for future research.
References for this review were identified through searches of PubMed as of July 2013, using the key words 'masked hypertension', 'isolated ambulatory hypertension', 'reverse white coat hypertension' or 'white coat normotension'. Searches were limited to publications in English. We reviewed the articles identified from these searches (612 published papers) and relevant references cited in these articles. We focused our review on masked hypertension in individuals not taking antihypertensive medications. However, where appropriate, we do briefly discuss masked hypertension in individuals taking antihypertensive medications.
DEFINITION
For the diagnosis of masked hypertension, non-elevated clinic BP is typically defined as o140/90 mm Hg. 6 However, the cutpoint for elevated out-of-clinic BP varies more than clinic BP in the published literature. Studies differ on whether mean awake ambulatory BP or mean 24-h ambulatory BP is used to define masked hypertension. 4, 7 The most widely used definition, by our group and other investigators, 8, 9 for elevated ambulatory BP has been a mean awake ambulatory BP X135/85 mm Hg. However, other definitions such as mean 24-h ambulatory BP X125/ 79 mm Hg 4 or X130/80 mm Hg 10 have been used.
Nighttime (or sleep) BP has also been used as a criterion for masked hypertension given the independent predictive value of nighttime BP for cardiovascular events. 11 The European Society of Hypertension position paper 12 incorporates elevated nighttime BP (X120/70 mm Hg) as part of the definition of masked hypertension: non-elevated clinic BP with elevated mean awake ambulatory BP and/or elevated mean 24-h ambulatory BP, and/or elevated mean nighttime ambulatory BP. Individuals with nonelevated clinic BP and elevated mean nighttime ambulatory BP have masked nocturnal hypertension. 12 Individuals with nonelevated clinic BP and elevated mean nighttime ambulatory BP with normal mean awake ambulatory BP have isolated (masked) nocturnal hypertension. 12 The term masked hypertension was originally used to describe individuals not taking antihypertensive medications. 5 However, many prevalence and outcome studies 4, 5, 7, 13 have also included participants on antihypertensive medications, which effectively combines two distinct masked hypertension populations (those not taking and those taking antihypertensive medications). The term 'masked uncontrolled hypertensives' has been used to describe treated individuals with non-elevated clinic but elevated ambulatory BP, whereas 'masked hypertension' has been used to describe untreated individuals. 12, 14 A recent European Society of Hypertension position paper 12 suggested that masked hypertension and masked uncontrolled hypertension be separately defined entities. Table 1 lists large (4500 participants) prospective cohort studies of masked hypertension in individuals recruited from the general population. As Table 1 shows, the overall prevalence in the general population ranges from 8.5 to 16.6%, and the prevalence ranges from 14.7 to 30.4% when restricted to participants with non-elevated clinic BP. The variability in prevalence estimates is attributed to the heterogeneous definition of masked hypertension, and differences in the sample characteristics and populations across studies.
PREVALENCE IN THE GENERAL POPULATION
In the United States, population estimates of masked hypertension are scarce. In a study of adult employees conducted in New York, we found that the prevalence of masked hypertension among those with non-elevated clinic BP who were not taking antihypertensive medications and had no history of overt CVD was 15.2%. 8 
CLINICAL IMPLICATIONS
Bjorklund et al. 15 demonstrated an increased risk of cardiovascular events with masked hypertension in a study of 578 untreated 70-year-old men in Sweden (Table 1) . After a mean 5.9 years of follow-up, compared with those with sustained normotension, the adjusted hazard ratio (HR) for cardiovascular morbidity was 2.77 (95% confidence interval (CI): 1.15-6.68) in the masked hypertension group and 2.94 (95% CI: 1.49-5.82) in the sustained hypertension group.
However, Hansen et al. 7 studied 1700 Danish men and women and demonstrated that compared with sustained normotension, only sustained hypertension and not masked hypertension had a statistically significant adjusted HR for cardiovascular mortality, ischemic heart disease and stroke: HR for sustained hypertension was 2.10 (95% CI: 1.45-3.06), whereas the HR for masked hypertension was 1.52 (95% CI: 0.91-2.54).
Meta-analyses have provided more consistent findings. Fagard and Cornelissen 3 published a meta-analysis of seven studies involving 11 502 participants-recruited not only from the general population (4 studies) but also from primary care clinics (2 studies) and specialty clinics (one study)-on the occurrence of cardiovascular events in people with white coat hypertension, masked hypertension and sustained hypertension. In two studies, home BP monitoring (HBPM) was used instead of ABPM to define masked hypertension. Over a mean follow-up of 8 years, compared with sustained normotension, the adjusted HRs for CVD events were 1.12 (95% CI: 0.84-1.50) for white coat hypertension, 2.00 (95% CI: 1.58-2.52) for masked hypertension and 2.28 (95% CI: 1.87-2.78) for sustained hypertension. The results did not differ significantly across the studies (P ¼ 0.89).
Investigators from Denmark, Belgium, Japan and Sweden created the International Database of Ambulatory BP in Relation to Cardiovascular Outcomes or IDACO database using eligible data from four population-based cohort studies, including ULSAM (Uppsala Longitudinal Study of Adult Men), Ohasama, MONICA 1 (Multinational Monitoring of Trends and Determinants in Figure 1 . Four hypertension categories based on clinic and ambulatory BP measurements. In sustained hypertension and sustained normotension, clinic BP and ambulatory BP categories agree. Sustained normotension is defined as non-elevated clinic and ambulatory BP. Sustained hypertension is defined as elevated clinic and ambulatory BP. White coat hypertension is defined as elevated clinic BP with normal ambulatory BP. Masked hypertension is defined as non-elevated clinic BP with elevated ambulatory BP. Elevated clinic BP is typically defined as X140/90 mm Hg. Elevated ambulatory BP is typically defined as mean awake ambulatory BP X135/85 mm Hg, although other cutpoints have been proposed (see review).
Cardiovascular Disease) and the Belgian Population Study. 16 Using individual-level data from this database, Hansen et al. 16 examined differences in cardiovascular risk in participants with white coat hypertension, masked hypertension and sustained hypertension in 7030 participants. At a median follow-up of 9.5 years (64 958 person years), compared with sustained normotension, the adjusted HRs for cardiovascular events were 1.22 (95% CI: 0.96-1.53) for white coat hypertension, 1.62 (95% CI: 1.35-1.96) for masked hypertension and 1.80 (95% CI: 1.59-2.03) for sustained hypertension. The HRs between masked hypertension and sustained hypertension were not significantly different (P ¼ 0.14).
Findings from most individual cohort studies, and results from two meta-analyses demonstrate that individuals with masked hypertension carry an increased cardiovascular risk compared with individuals with sustained normotension. The cardiovascular risk associated with masked hypertension approaches the risk associated with sustained hypertension.
MASKED HYPERTENSION IN SPECIAL PATIENT POPULATIONS Treated hypertension
The prevalence of masked hypertension may differ based on whether individuals are taking antihypertensive medications. For example, in a study by Franklin et al. 17 that examined 12 148 participants from the IDACO database, with masked hypertension defined as clinic BP o140/90 mm Hg and daytime ambulatory BP X135/85 mm Hg, among non-diabetic, clinic normotensives not on antihypertensive medications, 18.8% had masked hypertension. In contrast, among individuals taking antihypertensive medications, 30.5% had masked uncontrolled hypertension. Masked uncontrolled hypertension is also associated with an increased risk of mortality. A study by BenDov et al. 18 showed that among 2285 treated hypertensive patients, HRs for all-cause mortality were 1.88 (95% CI: 1.08-3.27) for masked uncontrolled hypertension and 2.02 (95% CI: 1.30-3.13) for sustained hypertension compared with white-coat uncontrolled hypertension.
Diabetes
Patients with diabetes have a higher prevalence of masked hypertension than patients without diabetes. 17, 19, 20 Among 7826 subjects from the IDACO database not taking antihypertensive medications, the prevalence of masked hypertension (clinic BP o140/90 mm Hg and daytime ambulatory BP X135/85 mm Hg) was higher in the clinic normotensive participants with diabetes (29.3%) than without diabetes (18.8%). 17 Over a median follow-up period of 11.0 years, in untreated diabetics, the adjusted risk for cardiovascular events for masked hypertensives was higher than Prevalence in the study sample (prevalence in participants with non-elevated clinic blood pressure). The referent group is participants with sustained normotension. Also, the most adjusted model is presented. In the PAMELA study, 4 exact HRs (95% CI) were not provided.
for sustained normotensives 21 showed that among 5693 hypertensive individuals from the Spanish ABPM Registry with CKD stages 1-5, the proportion of individuals with masked hypertension, defined by clinic BP (o140/90 mm Hg) and mean 24-h ambulatory BP (X130/80 mm Hg), was 7.0% in all individuals, and 32.1% of patients were with clinic normotension. In all, 72.6% of the participants were on antihypertensive medications. Using data from a cross-sectional study of 617 treated hypertensive African Americans with CKD from the African-American Study of Kidney Disease cohort study, Pogue et al. 13 reported that the prevalence of masked uncontrolled hypertension, defined as having controlled clinic BP (o140/90 mm Hg) but elevated daytime (X135/85 mm Hg) and/or elevated nighttime (X120/70 mm Hg) ambulatory BP was 70% among individuals with controlled clinic BP. Elevated nighttime ambulatory BP with or without elevated daytime ambulatory BP was the most common phenotype (94.3%) of masked hypertension. Masked uncontrolled hypertension was associated with increased proteinuria and left ventricular hypertrophy compared with those with controlled clinic BP or white coat hypertension. It is unclear what portion of the high prevalence of masked hypertension (70%) among individuals with controlled clinic BP was explained by antihypertensive medication use and/or by the presence of CKD.
Obstructive sleep apnea Baguet et al. 22 examined 133 newly diagnosed obstructive sleep apnea patients, free of known CVD and taking no medications, and found 39 patients (30.0%) exhibited masked hypertension defined as non-elevated clinic BP and a mean 24-h ambulatory BP X125/80 mm Hg. Interestingly, in 61 male clinic normotensive individuals free of known CVD and taking no medications, Drager et al. 23 found that obstructive sleep apnea was also associated with masked hypertension using mean awake ambulatory BP, suggesting that sleep apnea also adversely affects ambulatory BP beyond the sleep period. In a randomized controlled trial of 36 patients with obstructive sleep apnea on no medications randomized to either continuous positive airway pressure or no continuous positive airway pressure, Drager et al. 24 found that continuous positive airway pressure reduced clinic and ambulatory BPs, and the proportion of patients with masked hypertension fell from 39 to 5% (P ¼ 0.04) only in the continuous positive airway pressure group.
OTHER CORRELATES OF MASKED HYPERTENSION
Masked hypertension shares many of the same correlates as clinic hypertension, including increasing age, male gender, obesity, CKD and diabetes. 25, 26 However, these factors do not vary from the clinic to ambulatory settings, suggesting that there may be additional factors associated with the out-of-clinic setting that are associated with a selective increase in ambulatory BP over clinic BP.
Physical activity Although patients are instructed to rest for several minutes before clinic BP measurements, ABPM takes readings while the patient is active throughout the day. Exaggerated BP responses to physical activity or exercise may increase the likelihood of masked hypertension among patients with non-elevated clinic BP. Sharman et al. 27 examined the prevalence of masked hypertension among 72 untreated participants with a hypertensive response to exercise (defined as clinic BP o140/90 mm Hg and exercise systolic blood pressure (SBP) X210 mm Hg in men or X190 mm Hg in women, or diastolic blood pressure (DBP) X105 mm Hg). In this group, masked hypertension was highly prevalent (42 of 72 participants, 58%) and was associated with increased left ventricular mass index compared with participants with clinic normotension without a hypertensive response to exercise. In a group of 85 sedentary patients with diabetes and clinic normotension, Akilli et al. 25 demonstrated that masked hypertension was associated with decreased exercise capacity and exaggerated BP response on exercise treadmill testing. In a casecontrol study of patients with diabetes, Kramer et al. 28 showed that in 37 patients with sustained normotension and 24 patients with masked hypertension who all underwent exercise treadmill testing, the proportion of patients who reached a systolic peak value of 4180 mm Hg was higher in patients with masked hypertension (70.8%) than in those with sustained normotension (21.1%) and a peak SBP of 4170 mm Hg had 70% sensitivity and 73% specificity for identifying patients with masked hypertension. 28 It is possible that ABPM is detecting abnormally elevated BP in response to physical activity in the naturalistic setting that is not detected with clinic BP alone.
Mental stress In addition to physical stress, out-of-clinic BP measurements may also be influenced by psychological stress. To determine if psychosocial stress at work affects the prevalence of masked hypertension, Trudel et al. 29 obtained BP measurements from 2357 workers (mean age 44 years, 61% women). In men, having both high psychological demands and high decision latitude was associated with an odds ratio of 2.07 (95% CI: 1.30 À 3.31) for masked hypertension compared with the passive group. Interestingly, among women, there was no significant association between high psychological demands/high decision latitude and masked hypertension. In a study looking at working conditions and masked hypertension by Landsbergis et al., 30 45 men and 119 women hospital and home care employees/ volunteers were studied. Masked hypertension was observed in 24% of men and 17.6% of women with non-elevated clinic BPs, and was associated with evening, night and rotating shift work (odds ratio: 8.2; 95% CI: 2.1-40.3). A combination of job strain and effort-reward imbalance had an odds ratio of 3.0 (95% CI: 1.0-8.6) for masked hypertension after adjusting for age. In a meta-analysis of 22 cross-sectional studies looking at job strain and ambulatory BP, Landsbergis et al. 31 found that job strain was associated with a 3.4 mm Hg (95% CI: 2.0-4.8) increase in work systolic BP. These studies demonstrate an association between out-of-clinic jobrelated stress and BP that may increase the likelihood of masked hypertension.
Smoking and alcohol
In the meta-analysis by Verberk et al., 26 the investigators found that participants with masked hypertension were more often smokers than were participants with either sustained normotension, white coat hypertension or sustained hypertension. Ishikawa et al. 32 demonstrated that among 405 treated hypertensive patients with well-controlled clinic BPs, 246 patients (60.7%) had masked hypertension in the morning by HBPM. Patients who self-reported having at least one alcohol beverage every day had an increased odds ratio (1.76; 95% CI: 0.99-3.12; P ¼ 0.05) for morning-masked hypertension vs those who did not drink every day.
These out-of-clinic correlates of masked hypertension support the hypothesis that environmental factors are associated with BP in ways that are not detectable by clinic BP alone. Further research is required to determine if these associations are causal.
Biologic correlates Arterial stiffness, inflammation and endothelial dysfunction are associated with masked hypertension. Veerabhadrappa et al. 33 studied endothelial function and inflammation in 50 African Americans with clinic prehypertension and found that the 58% of patients with masked hypertension had impaired endothelial function and elevated levels of high sensitivity C-reactive protein compared with patients with true prehypertension (i.e., without elevated ambulatory BP). It is unclear whether these factors are selectively associated with masked hypertension or are also associated with sustained hypertension. It is possible that these biological correlates affect ambulatory BP first and then clinic BP, suggesting that masked hypertension is a precursor of sustained hypertension, which is a natural history we previously proposed. 8 Another possibility is that these biological factors interact with clinical and environmental factors to elevate BP outside the clinic setting in patients with masked hypertension. Because these associations are cross-sectional, causal direction cannot be ascertained. It is certainly possible that masked hypertension induces inflammation and endothelial function, rather than the other way around.
ISSUES RELATED TO PROPER DIAGNOSIS
In addition to the variation in the cutpoint used to define elevated ABP across studies, another source of variability in the diagnosis of masked hypertension is the number of valid ABPM readings required during either the awake or sleep period or 24-h period. 4, [7] [8] [9] An additional issue is whether HBPM is an acceptable alternative to ABPM for measuring out-of-clinic BPs. As noted above, the original definition of masked hypertension by Pickering et al. 5 indicated ABPM for the out-of-clinic BP assessment; however, some studies have used HBPM instead of ABPM. [34] [35] [36] [37] Viera et al. 10 evaluated the congruence of the diagnosis of masked hypertension comparing ambulatory and HBPM in 50 participants with normal or elevated clinic BP (110-159/70-99 mm Hg). Among the entire sample, ABPM and HBPM had only a 46.7% agreement in diagnosing masked hypertension when paired with their corresponding clinic BP measurement. In the PAMELA study, 4 home BP was elevated (defined as X135/83 mm Hg) in only half of the patients diagnosed with masked hypertension by mean 24-h ambulatory BP (defined as X125/79 mm Hg), again suggesting limited agreement between ambulatory and home BP readings in diagnosing masked hypertension. Finally, given that some studies have incorporated sleep BP in the definition of masked hypertension, 12,13 HBPM may not be an ideal methodology for identifying masked hypertension owing to the inability of most devices to measure BP during sleep.
Despite the poor agreement between ABPM and HBPM in diagnosing masked hypertension, the diagnosis of masked hypertension by ABPM vs HBPM may have similar prognostic value. Angeli et al. 38 performed a meta-analysis on the risk of major CVD in participants with masked hypertension stratified by out-of-clinic BP measurements with either ABPM or HBPM. They found the HR of major CVD to be 2.00 (95% CI: 1.54-2.60; Po0.001) for masked hypertension diagnosed by ABPM and 2.13 (95% CI: 1.35-3.35; P ¼ 0.001) for masked hypertension diagnosed by HBPM, suggesting that the risk associated with masked hypertension may not be affected by how out-of-clinic BP is measured. In the PAMELA study, 4 even though there was limited agreement between home and ambulatory BP readings in diagnosing masked hypertension, left ventricular mass index was similar between the participants who were diagnosed with masked hypertension by either 24-h ABPM or HBPM.
The poor agreement between ABPM and HBPM in diagnosing masked hypertension while having similar relations with endorgan damage and cardiovascular outcomes is interesting. It could imply that both forms of out-of-clinic BP measurements are identifying non-overlapping populations of people with masked hypertension and similar cardiovascular risk. Alternatively and probably less likely, it could reflect the inability of either measurement modality to pick up all cases of masked hypertension with a single set of measurements. As these studies did not examine the contribution of masked nocturnal hypertension, which cannot be determined by HBPM, further research is needed to better elucidate these issues.
An equally important, but perhaps underappreciated issue is how clinic BP is ascertained. Myers et al. 39 compared conventional (manual) vs automated measurement of BP in 555 patients with systolic hypertension and no serious comorbidities in 67 primary care practices and found that the average manual clinic BP (149.5/ 81.4 mm Hg) was significantly higher than automated measurements (135.6/77.7 mm Hg). These findings could reflect attenuation of the white coat response with the automated device. When compared with 24-h ambulatory monitoring as a gold standard, the accuracy of automated clinic BP measurements was significantly better than manual BP measurements. In a separate study, Myers et al. 40 demonstrated that the presence of masked hypertension was lower using automated clinic BP measurements. Across three clinic visits, masked hypertension was identified in a total of 42.1% single patient visits for automated clinic BP, and 60.7% single patient visits for manual clinic BP. It is plausible that the lower prevalence of masked hypertension associated with automated clinic BP reflects the greater correlation of ambulatory BP with automated vs manual clinic BP.
PRACTICAL APPROACH TO THE DIAGNOSIS OF MASKED HYPERTENSION
There is limited evidence on the best approach for detecting masked hypertension in individuals not taking antihypertensive medications. One approach would be to perform ABPM on everyone with non-elevated clinic BP. In 2011, based on a costeffectiveness analysis, the National Institute for Health and Care Excellence recommended that all patients with elevated clinic BP have ABPM to exclude white coat hypertension. 41 No study has been conducted on whether a parallel approach (i.e. performing ABPM in individuals with clinic normotension) would also be cost effective.
Given the added cost of ABPM, another approach would be to target screening to individuals whose risk for having masked hypertension exceeds some prespecified threshold. Our group has previously examined the diagnostic overlap between masked hypertension and prehypertension (SBP 120-139 mm Hg or DBP 80-89 mm Hg). 8 In a worksite-based study of 813 participants not on antihypertensive medications and free of CVD, 769 participants had non-elevated clinic BP. The overall prevalence of masked hypertension in the participants with non-elevated clinic BP was 15.2% using a cutoff of 135/85 mm Hg for mean awake ambulatory BP. In the subgroup of participants with prehypertension, the prevalence of masked hypertension increased to 34% and reached 52% in the higher prehypertensive range (SBP 130-139 mm Hg or DBP 80-89 mm Hg), whereas the prevalence of masked hypertension was only 3.9% in participants with normal clinic BP (SBP o120 mm Hg and DBP o80 mm Hg). Other studies have similarly shown that clinic BPs in the upper prehypertensive range predict masked hypertension. range ( Figure 2 ). If clinic BP is o120/80 mm Hg, there may be no need to do ABPM, as the prevalence of masked hypertension in this group is low. An additional approach would be to perform targeted testing among untreated individuals who have a high prevalence of masked hypertension, including those with diabetes, obstructive sleep apnea and possibly CKD.
Important questions remain including whether non-research clinic BPs obtained in routine practice can be used, whether this approach is valid across a broad range of age, gender and racial/ ethnic groups and whether HBPM is useful as an intermediary assessment tool for deciding on whom to perform ABPM.
TREATMENT
One approach to the treatment of masked hypertension would be to reduce ambulatory BP in masked hypertensives, using antihypertensive medications, despite the absence of elevated clinic BP and then perform periodic ABPM to determine on-treatment ambulatory BP. Although it is assumed that lowering ambulatory BP will have similar clinical benefits to lowering clinic BP, 43 it is still unclear if the treatment of masked hypertension is associated with a reduction in clinical adverse events. In a randomized, double-blind, placebo-controlled study, Hare et al. 44 examined the impact of fixed dose spironolactone (25 mg daily) in 115 untreated participants without a history of hypertension, but with a hypertensive response to exercise (exercise SBP X210 mm Hg in men or X190 mm Hg in women, or DBP X105 mm Hg). In a subgroup analysis of the 40% of participants with masked hypertension based on daytime ABPM using a cutoff of 135/85 mm Hg, the spironolactone group showed significantly greater reductions in exercise systolic BP ( À 10.0±12.9 vs 0.3±8.7 mm Hg, Po0.01) and 24-h ambulatory pulse pressure ( À 2.4 ± 4.7 vs 2.1 ± 8.4 mm Hg, Po0.05); effects on 24-h systolic and diastolic ambulatory BP were not reported. However, no difference in left ventricular mass index reduction was observed between the spironolactone and placebo groups after 3 months.
Another treatment paradigm is to consider masked hypertension as a prognostic marker of increased CVD and mortality, and rather than treating ambulatory BP, the focus would be on aggressively treating the modifiable risk factors associated with masked hypertension, including obesity, diabetes, sleep apnea and avoidance of smoking and alcohol intake. Masked hypertension may identify a 'high-risk' group that requires aggressive CVD risk factor control.
Given that there is some evidence that masked hypertension predicts subsequent sustained hypertension, 45 a third paradigm is to wait for individuals with masked hypertension to manifest sustained hypertension. This approach would include performing clinic BP measurements and ABPM at frequent intervals to diagnose sustained hypertension or exclude other phenotypes such as sustained normotension, and less commonly white coat hypertension, which may also follow an initial diagnosis of masked hypertension. 45 
FUTURE RESEARCH
Many important questions regarding masked hypertension remain unanswered. Table 2 summarizes relevant questions. To further unmask the extent of masked hypertension's public health impact and establish effective clinical screening and treatment guidelines, these questions should be addressed through focused research.
CONCLUSIONS
Masked hypertension is associated with an increased risk of cardiovascular morbidity and mortality compared with sustained normotension. If we assume that the prevalence of masked hypertension ranges from 15 to 30% in the US adult population of Figure 2 . A possible diagnostic approach for the identification of masked hypertension in the general population. approximately 160 million with non-elevated clinic BP, then currently it is estimated that 24 to 48 million American adults may be at increased risk for heart disease and stroke owing to masked hypertension. There are fundamental issues about masked hypertension that need to be addressed. These include standardizing the definition for diagnosis, comparing the cost-effectiveness of strategies for screening and detection, gaining further insight into the mechanisms that underlie masked hypertension and determining the optimal treatment strategy for treating masked hypertension. Until these issues are addressed, masked hypertension will likely remain outside mainstream clinical care, and this public health concern will be largely unaddressed.
